Webinar: non-viral cell engineering

RNS Number : 5521H

MaxCyte, Inc.

16 November 2018

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

MaxCyte to host webinar:

"Non-viral cell engineering: enabling a therapeutic revolution"             

Gaithersburg, Maryland - 16 November 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, will host a webinar, entitled "Non-viral cell engineering: enabling a therapeutic revolution," for investors and sell-side analysts between 15:00 - 16:00 GMT on Tuesday 20^th November 2018.

MaxCyte has established itself as a world leader in non-viral cell engineering - offering a rapid, safe and clinically-focused means of delivering the next generation of cell-based therapies, which is underlined by the Company's recent commercial and research partnerships with leading biotech companies including Kite, a Gilead Company; CRISPR Therapeutics; and Precision BioSciences.

This webinar will showcase and explain how MaxCyte's technology enables its partners to unlock the potential of their cutting-edge product development programs by giving them the means to create drugs using gene-editing technology in the treatment of inherited genetic diseases and cancer without using viral-vectors, which can be complicated and expensive to manufacture.

"Recent years have seen the emergence of a remarkable new class of cell-based therapies targeting many indications - from ultra-rare diseases affecting a handful of patients to some of the most common forms of cancer," said Doug Doerfler, President & CEO of MaxCyte, Inc. "These therapies are made possible by the extraordinary vision of scientists and clinicians and by a common core capability, the ability to engineer cells for patients."

"MaxCyte is at the forefront of this revolution in therapeutics and brings a uniquely powerful, validated and differentiated approach to cell engineering that is enabling pioneers in the industry to develop these new treatments as well as powering MaxCyte's own therapeutic development programs," he added. 

MaxCyte's business model provides not only a stable and growing recurring revenue stream from its technology access fees and disposable sales but offers significant medium- and long-term upside from potential milestone- and sales-based payments from its partners' therapeutic development programs. This has been demonstrated in the licence agreements recently entered into with CRISPR Therapeutics and Precision Biosciences. Milestones for MaxCyte's clinical licenses are generally followed by sales-based payments as products using MaxCyte's technology progress to commercialization.

The webinar will be followed by a Q&A session.

Please contact [e-mail] if you would like to attend. Log-in details and a detailed agenda for the webinar will be provided in advance of the event.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.  The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

MAXCYTE CONTACTS:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer		[phone]
Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji	[phone] [e-mail]

 

END

 

 

MSCGGGCCGUPRPPA